Viewing nowJanurodi 50 mg Tablets (Sitagliptin Hydrochloride Hydrate)
Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Kwangdong Pharmaceutical Co., Ltd.

MFDS item code 202004047 · Approved 2020.05.29 · Insurance code 641807060
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise to improve blood sugar control in patients with type 2 diabetes. It can be administered alone to newly diagnosed patients, and if blood sugar control is insufficient, it may be used in combination with metformin or other diabetes medications. If blood sugar control is difficult with existing monotherapy using sulfonylureas, metformin, thiazolidinediones, or insulin, this drug can be additionally administered to improve effects. Additionally, if blood sugar control is insufficient in a combination therapy regimen, this drug can be used together to enhance blood sugar management. It is a drug that helps systematically improve blood sugar control.
Administer 100 mg once daily as monotherapy or combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Assessment of renal function before starting treatment with this medicine and periodically thereafter is recommended, as dosage adjustment is required according to renal function. 1. No dosage adjustment is required in patients with mild renal impairment (eGFR ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.
This drug is an antidiabetic medication made from the ingredient sitagliptin. When taking this medication, serious allergic reactions may occur, so if symptoms such as itching, rash, difficulty breathing, or swelling of the face or neck appear, immediately stop taking the medication and consult a physician. Serious side effects such as pancreatitis, which causes inflammation of the pancreas, have been reported; if abdominal pain, nausea, or vomiting occurs after taking the medication, inform medical personnel immediately. This medication should not be administered to patients with type 1 diabetes, diabetic ketoacidosis, or to those with hypersensitivity to this drug or its components. Patients with decreased renal function may require dose adjustments due to delayed drug excretion, and it is advisable to have periodic kidney function tests. This drug may increase the risk of hypoglycemia when administered alone or in combination with other antidiabetic medications; therefore, blood sugar should be closely monitored, especially in patients taking insulin or sulfonylureas. If severe joint pain or blistering skin symptoms occur while taking this medication, notify a physician immediately, and discontinuation of the drug may be necessary if required. The safety of this drug has not been established in pregnant or lactating women, so its use is not recommended. Older adults may also have an increased risk of decreased renal function, thus requiring dose adjustments and kidney function monitoring. In case of overdose, gastrointestinal removal of the drug and clinical monitoring such as ECG should be performed, and some of the drug may be removed by hemodialysis. Finally, this medication has relatively few interactions with other drugs, but when taken with drugs like digoxin, blood levels should be closely monitored. If any unusual symptoms occur while taking the medication, consult a physician or pharmacist immediately.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air ingress, and it is best to keep it at room temperature between 1 to 30 degrees Celsius. This way of storage will help maintain the drug's effectiveness for a long time.
Light yellow-pink round film-coated tablet with a convex shape on both sides
30 tablets (10 tablets per PTX x 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Kwangdong Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.